TetraLogic Pharmaceuticals Corporation
Period Ending Dec 31, 2013 Dec 31, 2012
Total Revenue - -
Cost of Revenue - -
Gross Profit - -
Operating Expenses
Research and Development 9,523 12,096
Sales, General and Admin. 8,467 4,076
Non-Recurring Items - -
Other - -
Operating Income (17,991) (16,172)
Income From Continuing Operations
Add'l Income/Expense Items 808 46
Earnings Before Interest and Tax (17,183) (16,126)
Interest Expense 2,767 73
Earnings Before Tax (19,950) (16,199)
Income Tax - -
Minority Interest - -
Equity Earnings Unconsolidated Subsidiary - -
Net Income Cont. Operations (19,950) (16,199)
Non Recurring Events
Discontinued Operations - -
Extraordinary Items - -
Effect of Accounting Changes - -
Other Items - -
Net Income (19,950) (16,199)
Preferred Stock and Other Adjustments (3,250) (3,453)
Net Income Applicable to Common Shareholders (23,200) (19,653)